HOME > TOP STORIES
TOP STORIES
-
REGULATORY Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
-
BUSINESS Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
April 2, 2020
-
BUSINESS Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
-
BUSINESS Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
-
REGULATORY Global Health Confab Issues Proposals for Regulatory Harmonization in Asia
March 31, 2020
-
BUSINESS Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan
March 30, 2020
-
REGULATORY New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
-
REGULATORY PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
-
REGULATORY Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
-
REGULATORY Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
-
REGULATORY Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
-
BUSINESS Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
-
ACADEMIA Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
-
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
-
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
-
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
-
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
-
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review
March 18, 2020
-
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
-
ORGANIZATION Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
